Divozilimab vs Ocrevus Zunovo
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: CD20 · full Multiple Sclerosis pipeline
Divozilimab · Ivlizi
Marketed by Biocad
NCT05385744 · Phase 3 · completed
Randomized, double-blind, active-controlled Phase 3 trial (338 patients randomized 1:1) showing superior relapse reduction vs teriflunomide (PMID 38676683).
Reported efficacy
Annualized Relapse Rate (ARR): Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 (met)
Result source: NCT05385744
Ocrevus Zunovo
Marketed by Roche
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Divozilimab | Ocrevus Zunovo |
|---|---|---|
| Annualised relapse rate | —Not posted · NCT05385744 | —Not reported |
| Free of 3-month confirmed disability progression (%) | —Not posted · NCT05385744 | —Not reported |
| New or enlarging T2 lesions | —Not posted · NCT05385744 | —Not reported |
Annualised relapse rate
- Divozilimab
- —Not posted · NCT05385744
- Ocrevus Zunovo
- —Not reported
Free of 3-month confirmed disability progression (%)
- Divozilimab
- —Not posted · NCT05385744
- Ocrevus Zunovo
- —Not reported
New or enlarging T2 lesions
- Divozilimab
- —Not posted · NCT05385744
- Ocrevus Zunovo
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ocrevus Zunovo: registry results are on file for Multiple Sclerosis, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Divozilimab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divozilimab's landscape · Ocrevus Zunovo's landscape